SSRIs: Complete Antidepressant Guide

SSRI myths vs facts

Common SSRIs compared

The SSRIs differ in their uses, side-effect profiles and how hard they are to stop — not in how much they "work". This table compares them factually, without doses:

Related class: SNRIs (e.g. venlafaxine) raise both serotonin and noradrenaline, and the evidence shows more discontinuation symptoms with them than with most SSRIs. Which drug you are on matters for the stopping plan — a taper that suits one antidepressant may be far too quick for another.

Timeline: what to expect

Guidelines generally suggest continuing treatment for several months after you feel well, and longer for recurrent depression — the right duration is an individual decision with your doctor.

Common side effects

• Nausea (usually settles after 1–2 weeks; taking with food can help)
• Insomnia or excessive drowsiness (varies by person)
• Sexual side effects (reduced libido, delayed orgasm): affects roughly 30–40%
• Headache, dry mouth, sweating

Sexual side effects: reported in roughly 25% to 70% of people depending on how it is asked about, and frequently under-discussed. It does not always resolve on its own. Options — waiting, adjusting the treatment, switching to a lower-risk option such as bupropion or mirtazapine, or adding another medication — should always be discussed with your prescriber.

Stopping: what the evidence actually shows

Discontinuation symptoms are the part of antidepressant treatment most argued over, and both extreme accounts are unhelpful. A systematic review pooling 79 studies and 21,002 patients gives the most useful set of numbers currently available. Around 31% of people reported at least one symptom after stopping an antidepressant. But 17% reported symptoms after stopping placebo, a dummy tablet with nothing to withdraw from. Once that is accounted for, the incidence attributable to the drug itself came out at roughly 15%: about one person in six or seven. Severe symptoms were much less common, at about 2.8% after an antidepressant against 0.6% after placebo. Both things are true at once: discontinuation symptoms are real, and they are not what happens to most people who stop. The high placebo figure also means that experiencing symptoms does not prove the drug caused them — the underlying condition returning is a genuine alternative explanation, and telling those apart changes what should happen next. Which drug matters: the same review found discontinuation symptoms reported more often with desvenlafaxine, venlafaxine, imipramine and escitalopram, and rated as more severe with imipramine, paroxetine and venlafaxine or desvenlafaxine. Drugs that leave the body quickly tend to be harder to stop than those that clear slowly, which is why the taper that suits one antidepressant may be far too quick for another.

Dependence is not the right word

Discontinuation symptoms are often described, including by people experiencing them, as withdrawal from an addictive drug. The comparison is understandable, and it is not accurate. Antidepressants do not produce craving, do not drive dose escalation to chase an effect, and are not sought compulsively. What happens is that the brain adjusts to the drug's presence and needs time to readjust to its absence — the same thing that happens with several medicines nobody calls addictive. The distinction matters because the wrong word leads to the wrong action: people who believe they are addicted sometimes stop abruptly to get it over with, which is precisely what produces the worst symptoms.

How to stop an SSRI safely

• Never stop abruptly: this causes discontinuation symptoms (dizziness, electric-shock sensations, flu-like symptoms).
• Reduce gradually over weeks to months, with the pace agreed with your prescriber — slower at the lower amounts, where each reduction is proportionally larger.
• Fluoxetine's long half-life often allows a simpler stopping plan than shorter-acting SSRIs.
• If symptoms return during a reduction, slow down and discuss with your doctor.

Serotonin syndrome: a dangerous drug interaction

Serotonin syndrome is a potentially life-threatening condition caused by excess serotonergic activity in the nervous system. It most often occurs when an SSRI is combined with another medicine that also raises serotonin. The highest-risk combinations include SSRIs with monoamine oxidase inhibitors (MAOIs), and with other serotonin-raising drugs such as tramadol, linezolid, St John's wort, and some migraine treatments (triptans). Symptoms include agitation, confusion, sweating, tremor, muscle rigidity, high temperature and rapid heartbeat. Always tell any prescriber that you take an SSRI, and never start or stop a medicine that affects serotonin without medical advice.

Hyponatraemia: low blood sodium in older adults

SSRIs can lower blood sodium (hyponatraemia), particularly in older adults. Symptoms — confusion, unsteadiness, falls, drowsiness — can be mistaken for something else, so a low threshold for checking sodium is important in older patients starting or continuing an SSRI. Report new confusion or unsteadiness promptly.

Pharmacist's practical notes

The first weeks on an antidepressant deserve close attention: keep brief notes on mood, sleep, appetite, and any side effects, and keep every follow-up appointment, because drug choices are adjusted from exactly this information. Seek help urgently — from your doctor, a trusted person, or emergency services — if thoughts of harming yourself appear or worsen, as this risk can rise early in treatment, especially in younger people. Also report new agitation, restlessness, or unusual behaviour changes.

Several combinations need a doctor's or pharmacist's review. Painkillers such as NSAIDs and blood thinners combined with SSRIs raise bleeding risk; St John's wort and certain migraine medicines can push serotonin too high, risking serotonin syndrome; and alcohol can worsen depression, anxiety, and side effects. Give every prescriber and pharmacist your complete medicine list, including herbal products.

Store at room temperature in the original pack. Antidepressants usually take weeks to show their full effect, which is why stopping early — because you feel no different yet, or because you feel better — undermines treatment. Never stop suddenly: discontinuation symptoms such as dizziness, vivid dreams, and electric-shock sensations are common, so any stop or switch needs a doctor-planned taper.

Tell your doctor about the antidepressant before any surgery, since some SSRIs affect bleeding and anaesthetists review all medicines. If pregnancy is planned or possible, raise it early: the decision to continue, switch, or stop involves balancing the risks of untreated depression against medicine exposure, and it belongs in a careful conversation with your doctor, not a unilateral decision.

In India

Generic SSRIs are typically affordable in India, though prices vary by brand, molecule, and city. Cost should never be the reason for stopping — ask your doctor or pharmacist about quality generic options if price is a burden.

Antidepressants are prescription medicines in India. Follow your own prescription; never start, stop, or change a dose without your doctor.

Frequently Asked Questions

References

The clinical information on this page is drawn from peer-reviewed sources indexed by the US National Library of Medicine. Links go to the source so you can read it yourself.

1. Selective Serotonin Reuptake Inhibitors. In: StatPearls. Treasure Island (FL): StatPearls Publishing. NCBI Bookshelf NBK554406
2. Sertraline. In: StatPearls. Treasure Island (FL): StatPearls Publishing. NCBI Bookshelf NBK547689
3. Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024;11(7):526–35. PMID 38851198 · doi:10.1016/S2215-0366(24)00133-0
4. Rang ST, Field J, Irving C. Serotonin toxicity caused by an interaction between fentanyl and paroxetine. Can J Anaesth. 2008;55(8):521–5. PMID 18676387 · doi:10.1007/BF03016672
5. Mannesse CK, Jansen PAF, Van Marum RJ, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. Maturitas. 2013;76(4):357–63. PMID 24094459 · doi:10.1016/j.maturitas.2013.08.010